Skip to main content
. 2021 Jan 13;6(4):881–893. doi: 10.1016/j.ekir.2020.12.035

Figure 1.

Figure 1

Overview of different dosing regimens used in clinical trials (blue boxes) and a potential algorithm for subsequent dosing as recommended by current Kidney Disease : Improving Global Outcomes guidelines (green boxes).

CYC, cyclophosphamide; PLA2R Ab, M-type phospholipase A2 receptor antibody; PR, partial remission.

∗ In « high-dose regimens » using a second course of the initial rituximab dosing after 6 months, KDIGO recommendations for subsequent dosing in the first 6 months are not applicable (gray arrows). Nonetheless, subsequent dosing may be guided similarly thereafter.